Migraine preventive drug-induced weight gain may be mediated by effects on hypothalamic peptides: The results of a pilot study

Stefano Caproni, Ilenia Corbelli, Luigi Alberto Pini, Maria Letizia Cupini, Paolo Calabresi, Paola Sarchielli

Research output: Contribution to journalArticlepeer-review

Abstract

Aims: This study was aimed to verify changes in the levels of hypothalamic neuropeptides in migraineurs under preventive treatment with amitryptiline and flunarizine. Thirty-nine migraine patients with a body mass index 2 and without endocrinological or metabolic diseases were assigned to two treatment groups, one receiving amitryptiline, the other flunarizine, for 3 months. Orexin-A, orexin-B and neuropeptide-Y plasma levels were measured at the basal time, at the 1st, 2nd and 3rd months of preventive treatment. Results: A statistically significant reduction in plasma orexin-A and orexin-B levels emerged in both groups. Conversely, plasma neuropeptide-Y levels were markedly increased, with the highest levels at the 2nd and 3rd months, in both patient groups. Orexin-A levels were also negatively correlated to weight gain in both groups during the treatment period. Conclusions: These results suggest that changes in the levels of hypothalamic orexinergic peptides may contribute to body weight increase occurring in migraineurs during amitryptiline or flunarizine prophylactic treatment.

Original languageEnglish
Pages (from-to)543-549
Number of pages7
JournalCephalalgia
Volume31
Issue number5
DOIs
Publication statusPublished - May 2011

Keywords

  • amytryptiline
  • Flunarizine
  • migraine
  • neuropeptide-Y
  • orexin

ASJC Scopus subject areas

  • Clinical Neurology

Fingerprint Dive into the research topics of 'Migraine preventive drug-induced weight gain may be mediated by effects on hypothalamic peptides: The results of a pilot study'. Together they form a unique fingerprint.

Cite this